- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.04. | HROW, HCAT and EGRX are among after hour movers | 3 | Seeking Alpha | ||
| 25.03. | Harrow CEO Mark Baum buys $104k in company stock | 2 | Investing.com | ||
| 22.03. | Opaleye Management buys $488k of Harrow Inc. shares | 1 | Investing.com | ||
| 21.03. | Earnings call: Harrow Health reports record revenues, optimistic outlook | 2 | Investing.com | ||
| 20.03. | Why Is Harrow (HROW) Stock Up 5% Today? | 1 | InvestorPlace | ||
| 20.03. | Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session | 8 | Benzinga.com | ||
| 20.03. | Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M | 1 | Seeking Alpha | ||
| 19.03. | Harrow Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
| 19.03. | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | 84 | Business Wire | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| 19.03. | Harrow: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 19.03. | HARROW, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | HARROW, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | Harrow Health Q4 2023 Earnings Preview | 1 | Seeking Alpha | ||
| 18.03. | Earnings Preview: Harrow Health | 1 | Benzinga.com | ||
| 21.02. | Here's How Harrow (HROW) Weighed on SRK Capital's Performance | 1 | Insider Monkey | ||
| 15.02. | HARROW, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.01. | HARROW, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.01. | Harrow says dry eye drug Vevye now available in US | 1 | Seeking Alpha | ||
| 03.01. | HARROW, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.11.23 | Harrow Recent Insider Activity | 2 | Benzinga.com |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,275 | +1,78 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer vor Zahlen fürs erste Quartal auf "Neutral" mit einem Kursziel von 30 US-Dollar belassen. Der Pharmakonzern dürften die... ► Artikel lesen | |
| GILEAD SCIENCES | 62,41 | +0,40 % | Virushepatitis bis 2030 eliminieren: Gilead Sciences fördert zahlreiche Projekte weltweit mit 4 Millionen US-Dollar - auch in Deutschland | Martinsried bei München (ots) - - Gilead vergibt 4 Millionen US-Dollar weltweit (ohne die Vereinigten Staaten) durch das Förderprogramm "ALL4LIVER Grant" -- Die World Hepatitis Alliance und hochrangige... ► Artikel lesen | |
| MERCK & CO | 118,20 | +0,51 % | Health Canada Approves Merck's Keytruda Plus Chemotherapy To Treat Gastric Cancers | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Friday said its Keytruda in combination with fluoropyrimidine- and platinum-containing-chemotherapy has been approved by Health Canada for... ► Artikel lesen | |
| ELI LILLY | 680,20 | -2,87 % | Eli Lilly, SuperMicro und mehr: Die 10 überbewertesten Tech-Aktien im S&P 500 | © Foto: Peter Morgan - picture alliance/AP Images Angesichts der aktuellen Marktschwankungen warnen Experten vor überbewerteten Aktien - darunter namhafte S&P-500-Unternehmen.Die wichtigsten US-Indizes... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 370,40 | +0,20 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter -
Successful completion of end-of-phase 2... ► Artikel lesen | |
| MPH HEALTH CARE | 21,000 | +7,14 % | EQS-News: MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände | EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 16,890 | +2,67 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients... ► Artikel lesen | |
| INCYTE | 49,250 | -0,75 % | Medikament des Jahres - Auszeichnung für Incyte | München (ots) - Das bundesweite Netzwerk spezialisierter und innovativer Dermatologen, onkoderm e. V., hat auf der diesjährigen DERM Frankenthal, der größten Fachtagung für niedergelassene Hautärzte... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 80,81 | -0,52 % | Behind the Scenes of Edwards Lifesciences' Latest Options Trends | ||
| IONIS PHARMACEUTICALS | 38,130 | -0,55 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
| BIONANO GENOMICS | 0,761 | -2,62 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,400 | +5,05 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 9,554 | -1,29 % | Adhoc: Spexis AG: Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera | Spexis AG / Key word(s): Miscellaneous
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,157 | +1,42 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 137,45 | +0,84 % | Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC | SOUTH SAN FRANCISCO (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) presented KARDIA-2 Phase 2 study results of zilebesiran for the treatment of hypertension at the 2024 American College of... ► Artikel lesen |
Das Unternehmen HARROW INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,180 (-1,66 %) liegt der Kurs bei 10,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
